While recent studies could not detect a predisposition for leukemia based on presence or absence of particular inhibitory and stimulatory KIR genes or KIR haplotype classification, there is growing evidence for beneficial effects of KIR B genotype donors in HSCT for AML. This evidence concerns the gene KIR3DL1 and leukemia.